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(57) Abstract: Provided herein are methods of producing an acellular tissue product wherein the method can include the step of in-
ducing apoptosis and washing the tissue after induction of apoptosis with a tonic solution. Also provided herein are acellular tissue 
products produced by the methods provided herein and methods of administering the acellular tissue products to a subject in need 
thereof. 
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TISSUE DECELLULARIZATION METHODS 
CROSS-REFERENCE TO RELATED APPLICATIONS 
This application claims the benefit of and priority to co-pending U.S. Provisional 
Patent Application No. 62/192,823, filed on July 15, 2015, entitled "TISSUE 
5 DECELLULARIZATION METHODS," the contents of which is incorporated by reference 
herein in its entirety. 
BACKGROUND 
Decellularization technology offers the potential to attain tissue-specific scaffolds that 
10 guide tissue regeneration following injury and/or disease. As such there exists a need for 
improved decllularization methods for scaffold generation for tissue regeneration for 
treatment of injury and/or disease. 
15 
SUMMARY 
Provided herein are tissue decellularization methods, where the methods can include 
the steps of obtaining a tissue sample from a subject to generate an ex vivo tissue sample; 
exposing the ex vivo tissue sample to an apoptotic agent or apoptotic process; and washing 
the ex vivo tissue sample in a hypertonic solution, a hypotonic solution, or a hypertonic 
solution and a hypotonic solution. The tissue sample can be a peripheral nerve, a nucleus 
20 pulposus, and/or a combination thereof. The tissue sample can be a lung tissue. The 
apoptotic agent is camptothecin, staurosporine, doxorubicin, or an analog thereof. The 
apoptotic process can contain one or more freeze-thaw cycles. The concentration of the 
apoptotic agent can range from about 5IJM to about 10 IJM. The concentration of the 
apoptotic agent can be about 10 IJM. The concentration of the apoptotic agent can be about 
25 5 IJM. The ex vivo tissue sample can be exposed to the apoptotic agent for about 2 days. 
The tissue can be washed with a hypertonic solution. The hypertonic solution can be greater 
than 1X buffered solution. The hypertonic solution is 4X saline. The tissue can be washed 
with a hypotonic solution. The hypotonic solution can less than 1X buffered solution. The 
hypotonic solution can be a 0.5X saline solution. The concentration the concentration of the 
30 apoptotic agent can be about 5 IJM. The apoptotic agent can be camptothecin, 
staurosporine, doxorubicin, or an analog thereof. The method can further include the step of 
treating the tissue with DNAse for a period of time ranging from 30 minutes to 24 hours. The 
step of washing can produce an acellular tissue product. The method can further include 
step of adding an active agent to the acellular tissue product. The active agent can selected 
35 from the group consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide, 
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antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit translation or 
transcription of essential tumor proteins and genes, hormone, immunomodulator, antipyretic, 
anxiolytic, antipsychotic, analgesic, antispasmodic, anti-inflammatory, anti-histamine, anti-
infective, a chemotherapeutic, or combinations thereof. 
5 Also provided herein are acellular tissue products, where the acellular tissue product 
can be formed by a method as described herein. The method can further include the step of 
treating the tissue with DNAse for a period of time ranging from about 30 minutes to about 
24 hours. The acellular tissue product can contain an active agent. The active agent can be 
selected from the group consisting of: a stem cell, nucleic acid, amino acid, peptide, 
10 polypeptide, antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit 
translation or transcription of essential tumor proteins and genes, hormone, 
immunomodulator, antipyretic, anxiolytic, antipsychotic, analgesic, antispasmodic, anti-
inflammatory, anti-histamine, anti-infective, a chemotherapeutic, or combinations thereof. 
The acellular tissue product can be formulated for injection. 
15 Also provided herein are methods including the step of administering an acellular 
tissue product as provided herein to a subject in need thereof. The subject in need thereof 
can have a spinal injury or disease, intervertebral disc degeneration, disease or trauma of 
the lungs or liver, or volumetric muscle loss, peripheral nerve injury, amputation or spinal 
degradation, osteoarthritis of the hip or knee, volumetric muscle loss, cirrhosis of the liver, or 
20 otherwise requires partial or total organ replacement. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Further aspects of the present disclosure will be readily appreciated upon review of 
the detailed description of its various embodiments, described below, when taken in 
25 conjunction with the accompanying drawings. 
Fig. 1 shows one embodiment of a method for decellularization of a tissue sample. 
Figs. 2A-2F show fluorescence micrographs of peripheral nerve with and without 
apoptosis induction followed by washing with various regimens. 
Fig. 3 shows a graph demonstrating DNA content of peripheral nerve under various 
30 treatment regimens. 
Fig. 4 shows a table demonstrating the quantification of DNA content shown in Fig. 3. 
Figs. 5A-5C demonstrate fluorescence micrographs of nerve tissue labeled for cell or 
basal lamina markers. For Figs. 5A and 58, the images are fresh nerve (top half) and 
apoptosis decellularized nerve (bottom half). Fig. 5A was labeled for neurons (neurofilament, 
35 green), 8chwann cells (8100, red), and nuclei (DAPI, blue). Fig. 58 shows cross-sections of 
2 
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the basal lamina stained for laminin (red). Fig. 5C shows a representative basal lamina 
staining in nerve tissue decellularized according to a conventional detergent-based method. 
Figs. 6A-6D demonstrate fluorescence micrographs of nucleus pulposus stained with 
a nuclear stain (blue) and a chondroitin sulfate proteoglycan (CSPG) antibody (red). 
Figs. 7 A-7B demonstrate images of a carefully dissected motion segment of the 
spine and an extracted nucleus pulposus. 
Fig. 8 shows a graph demonstrating tibialis anterior muscle weight changes over time 
in rats receiving detergent decellularized nerve graft, apoptosis decellularized nerve graft, or 
an isograft of fresh nerve. This figure demonstrates that the apoptosis decellularization 
10 method was not statistically different from isograft after 8 weeks, suggesting that the 
apoptosis decellularization method has the potential to perform similarly to the clinical gold 
standard and outperform traditional decellularization methods. 
Figs. 9A-9C show fluorescence images demonstrating that the more gentle apoptosis 
decellularization (Fig. 9C) process can result in less tissue disruption than the harsher 
15 traditional decellularization methods which uses a water treatment to initiate decellularization 
(Fig. 9B), and more comparable to fresh nerve (Fig. 9A). 
DETAILED DESCRIPTION 
Before the present disclosure is described in greater detail, it is to be understood that 
20 this disclosure is not limited to particular embodiments described, and as such may, of 
course, vary. It is also to be understood that the terminology used herein is for the purpose 
of describing particular embodiments only, and is not intended to be limiting. 
Where a range of values is provided, it is understood that each intervening value, to 
the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between 
25 the upper and lower limit of that range and any other stated or intervening value in that 
stated range, is encompassed within the disclosure. The upper and lower limits of these 
smaller ranges may independently be included in the smaller ranges and are also 
encompassed within the disclosure, subject to any specifically excluded limit in the stated 
range. Where the stated range includes one or both of the limits, ranges excluding either or 
30 both of those included limits are also included in the disclosure. 
Unless defined otherwise, all technical and scientific terms used herein have the 
same meaning as commonly understood by one of ordinary skill in the art to which this 
disclosure belongs. Although any methods and materials similar or equivalent to those 
described herein can also be used in the practice or testing of the present disclosure, the 
35 preferred methods and materials are now described. 
3 
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All publications and patents cited in this specification are herein incorporated by 
reference as if each individual publication or patent were specifically and individually 
indicated to be incorporated by reference and are incorporated herein by reference to 
disclose and describe the methods and/or materials in connection with which the 
5 publications are cited. The citation of any publication is for its disclosure prior to the filing 
date and should not be construed as an admission that the present disclosure is not entitled 
to antedate such publication by virtue of prior disclosure. Further, the dates of publication 
provided could be different from the actual publication dates that may need to be 
independently confirmed. 
10 As will be apparent to those of skill in the art upon reading this disclosure, each of the 
individual embodiments described and illustrated herein has discrete components and 
features which may be readily separated from or combined with the features of any of the 
other several embodiments without departing from the scope or spirit of the present 
disclosure. Any recited method can be carried out in the order of events recited or in any 
15 other order that is logically possible. 
20 
25 
Embodiments of the present disclosure will employ, unless otherwise indicated, 
techniques of molecular biology, microbiology, nanotechnology, organic chemistry, 
biochemistry, botany and the like, which are within the skill of the art. Such techniques are 
explained fully in the literature. 
Definitions 
As used herein, "about," "approximately," and the like, when used in connection with 
a numerical variable, generally refers to the value of the variable and to all values of the 
variable that are within the experimental error (e.g., within the 95% confidence interval for 
the mean) or within ±10% of the indicated value, whichever is greater. 
As used herein, "administering" refers to an administration that is oral, topical, 
intravenous, subcutaneous, transcutaneous, transdermal, intramuscular, intra-joint, 
parenteral, intra-arteriole, intradermal, intraventricular, intracranial, intraperitoneal, 
intralesional, intranasal, rectal, vaginal, by inhalation or via an implanted reservoir. The term 
"parenteral" includes but is not limited to, subcutaneous, intravenous, intramuscular, intra-
30 articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial 
injections or infusion techniques. 
As used interchangeably herein, "subject," "individual," or "patient," refers to a 
vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not 
limited to, murines, simians, humans, farm animals, sport animals, and pets. The term "pet" 
35 includes a dog, cat, guinea pig, mouse, rat, rabbit, ferret, and the like. The term farm animal 
includes a horse, sheep, goat, chicken, pig, cow, donkey, llama, alpaca, turkey, and the like. 
4 
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As used herein, "control" is an alternative subject or sample used in an experiment 
for comparison purposes and included to minimize or distinguish the effect of variables other 
than an independent variable. 
As used herein, "positive control" refers to a "control" that is designed to produce the 
5 desired result, provided that all reagents are functioning properly and that the experiment is 
properly conducted. 
As used herein, "negative control" refers to a "control" that is designed to produce no 
effect or result, provided that all reagents are functioning properly and that the experiment is 
properly conducted. Other terms that are interchangeable with "negative control" include 
10 "sham," "placebo," and "mock." 
15 
As used herein, "autologous" refers to being derived from the same subject that is the 
recipient. 
As used herein, "allograft" refers to a graft that is derived from one member of a 
species and grafted in a genetically dissimilar member of the same species. 
As used herein "xenograft" or "xenogeneic" refers to a substance or graft that is 
derived from one member of a species and grafted or used in a member of a different 
species. 
As used herein, "autograft" refers to a graft that is derived from a subject and grafted 
into the same subject from which the graft was derived. 
20 As used herein, "allogeneic" refers to involving, derived from, or being individuals of 
the same species that are sufficiently genetically different so as to interact with one another 
antigenically. 
As used herein, "donor" refers to a subject from which cells or tissues are derived. 
As used herein, "hypertonic solution" refers to a solution that has a greater 
25 concentration of solutes than the concentration of solutes inside of a cell. 
As used herein, "hypotonic solution" refers to a solution that has a concentration of 
solutes that is less than the concentration of solutes within a cell. 
As used herein, "analog" refers to another compound, composition, or other 
substance of matter that is considered comparable to the reference compound, composition, 
30 or substance of matter and includes structural analogs and functional analogs. 
Discussion 
Decellularization technology offers the potential to attain tissue-specific scaffolds that 
guide tissue regeneration following injury and/or disease. Most decellularization protocols 
used in research and industry contain an initial cell lysis step in a hypotonic buffer, such as 
35 water, followed by chemical solutions to remove cellular remnants. These harsh conditions 
result in an undesirable broad dispersal of intracellular components, disruption of tissue 
morphology, and removal of desired tissue elements. 
5 
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With that said, described herein are decellularization methods that do not require cell 
lysis buffers or harsh chemicals. The decellularization methods described herein can include 
inducing apoptosis in ex vivo tissue. The decellularization methods described herein can 
effectively remove cellular components without having to rely on harsh conditions. In some 
5 embodiments, the methods can effectively remove cellular components from peripheral 
nerve and/or nucleus pulposus. In addition to reducing time, labor, and expense of 
decellularization, some embodiments described herein can only need one step for inducing 
apoptosis and one step for washing the cells. 
Other compositions, compounds, methods, features, and advantages of the present 
10 disclosure will be or become apparent to one having ordinary skill in the art upon 
examination of the following drawings, detailed description, and examples. It is intended that 
all such additional compositions, compounds, methods, features, and advantages be 
included within this description, and be within the scope of the present disclosure. 
15 
Methods 
Described herein are methods of decellularization that include inducing apoptosis in 
an ex vivo tissue sample, where tissue wide apoptosis can be induced by exposing the 
tissue to an apoptosis-inducing agent or apoptosis inducing process for a time period. 
Induction of apoptosis in the ex vivo tissue sample can cause cell detachment from the 
tissue extracellular matrix, degradation of intracellular DNA, RNA and proteins, and 
20 allocation into apoptotic bodies, which can be removed using mild hypotonic and/or mild 
hypertonic buffered solutions. 
As shown in Fig. 1, the method 1000 can begin with obtaining a tissue sample from a 
subject or other donor source 1010. The tissue can be autologous, xenogeneic, allogeneic, 
or syngeneic. In some embodiments, the tissue can be obtained from anywhere in a subject. 
25 In some embodiments, the tissue sample can be obtained from the periphery or spinal 
column of a subject. In some embodiments, the tissue can be a peripheral nerve and/or 
nucleus pulposus. In other embodiments, the tissue can be brain, spinal cord, heart, lung, 
liver, muscle, cartilage, tendons, ligaments, menisci, stomach, intestine, pancreas, and/or 
kidney. In further embodiments, the tissue is blood vessels, bone, and/or cornea. 
30 After the tissue sample has been obtained, apoptosis can be induced 1020 in the ex 
vivo tissue sample by exposing the ex vivo tissue sample to an apoptotic agent (i.e. a 
compound and/or composition that induces apoptosis in a cell) for a time period. In some 
embodiments, apoptosis can be induced by an apoptotic process (i.e. a process that can 
include one or more steps that induces apoptosis). In some embodiments, the apoptotic 
35 agent can be camptothecin, staurosporine, doxorubicin, and/or analogs thereof, or any other 
agent or process that induces apoptosis. In other embodiments, the apoptotic agent could be 
nitric oxide, hypoxia, pH, or hydrogen peroxide. In some embodiments where an apoptotic 
6 
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agent is used to induce apoptosis, the ex vivo tissue sample can be exposed to the apoptotic 
agent for any length of time, including but not limited to, greater than about 1 hour, about 1 
hour to about 10 days, about 1 hour to about 7 days, about 1 hour to about 4 days, about 1 
hour to about 2 days, or about 1 hour to about 1 day. In some embodiments, the ex vivo 
5 tissue sample can be exposed to camptothecin or analog thereof for 2 days. In some 
embodiments, the tissue ex vivo tissue sample can be exposed to the apoptotic agent, such 
as camptothecin, for about 1 day. 
The ex vivo tissue sample can be exposed to a solution containing a concentration of 
the apoptotic agent and/or to an apoptotic process. In some embodiments, the apoptotic 
10 process does not use an apoptotic agent. In embodiments that employ an apoptotic agent, 
the concentration of the apoptotic agent can range from about 1 nM to about 1 mM or 
greater. In some embodiments, the concentration of the apoptotic agent can range from 
about 1 IJM to about 1 OOIJM. I n some embodiments, the concentration of the apoptotic 
agent can be about 101JM. In some embodiments, the ex vivo tissue sample can be exposed 
15 to 10 IJM of camptothecin or an analog thereof. In some embodiments, the ex vivo tissue 
sample can be exposed to 10 IJM of camptothecin or an analog thereof for about 2 days. In 
some embodiments, the concentration of the apoptotic agent can range from about 5 IJM to 
about 10 IJM. In some embodiments, the concentration of the apoptotic agent is about 5 IJM. 
In some embodiments, the ex vivo tissue sample can be exposed to 5 IJM camptothecin or 
20 an analog thereof. In some embodiments, the ex vivo tissue sample can be exposed to 5 IJM 
of camptothecin or an analog thereof for about 1 day. 
In some embodiments, the apoptotic process includes exposure of the ex vivo tissue 
to one or more freeze-thaw cycles to induce apoptosis. 
After the ex vivo tissue sample can be exposed to an apoptotic agent or process for a 
25 desired amount of time, the tissue sample can be washed 1030 with one or more washes 
with one or more buffered solutions to facilitate cell removal. The ex vivo tissue sample can 
be washed with one or more washes of a hypertonic buffered solution (i.e. greater than 1X 
buffered solution). In some embodiments the number of washes ranges from one to six. In 
some embodiments, the hypertonic solution can be a 1.01X-10X buffered solution. In some 
30 embodiments, the concentration can be 4X with an intermediate 2X wash. The tissue sample 
can be washed with one or more washes of a hypotonic buffered solution (i.e. less than 1X 
buffered solution). In some embodiments, the hypotonic solution can be a 0.01X up to a 
0.99X buffered solution. In embodiments, the buffered solution is a saline solution at the 
given concentrations to result in a hypotonic or hypertonic solution. The starting saline 
35 solution can be isotonic. The starting saline solution can have a formulation of 10X which is 
diluted with water to attain various hypertonic washes. While not being bound to theory, it is 
believed that DNA removal occurs under the hypotonic wash conditions, while protein 
7 
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removal occurs under the hypertonic wash conditions. Some embodiments employ only 
hypertonic washes. Other embodiments employ only hypotonic washes. Yet further 
embodiments employ both hypertonic and hypotonic washes. 
In some embodiments, the method 1000 can also include an optional step of DNAse 
5 treatment 1040. The DNAse treatment can occur after the wash(es) previously performed 
1030. In some embodiments, the optional DNAse treatment 1040 is performed after 
hypotonic washes 1030 were performed. In some embodiments where the optional DNAse 
1040 treatment is performed, only hypertonic washes have been performed. In 
embodiments, the concentration of DNAse can range from 25 U/mL to 250 U/ mL. The 
10 preferred concentration is 75 U/mL. The DNase can be any suitable DNase. The DNase 
treatment can be performed at a temperature ranging from about 4 to about 3rC. The 
preferred temperature is 25°C. It will be appreciated by those of ordinary skill in the art that 
the temperature can be dependent on the temperature that the DNase has optimal activity. 
The time period for the DNase treatment can range from about 30 minutes or less to 1, 2, 3, 
15 4,5,6,7,8,9,10,11,12,24, or 36 hours or more. The treatment time can vary based on 
tissue type, but in some embodiments the treatment time is 18-24 hours. 
The method 1000 can produce an acellular tissue. The resulting acellular tissue can 
be used as a scaffold substrate for three dimensional (3D) cell culture and tissue 
engineering techniques. Further, the resulting acellular tissue can be delivered to a subject 
20 in need thereof to facilitate the in vivo generation and/or regeneration of cells and tissues 
within the subject. The resulting acellular tissue product can be formulated to be delivered to 
a subject in need thereof by any suitable method of deliver, including but not limited to, 
implantation or injection. The acellular tissue products can be enhanced by the addition of 
one or more other agents or compounds to the acellular tissue product, including without 
25 limitation other cells (e.g. stem cells or other progenitor cells), nucleic acids, amino acids, 
peptides, polypeptides, antibodies, aptamers, ribozymes, guide sequences for ribozymes 
that inhibit translation or transcription of essential tumor proteins and genes, hormones, 
immunomodulators, antipyretics, anxiolytics, anti psychotics, analgesics, antispasmodics, 
anti-inflammatories, anti-histamines, anti-infectives, and chemotherapeutics. In some 
30 embodiments, the acellular tissue products can be co-administered with one or more other 
agents or compounds, including without limitation other cells (e.g. stem cells or other 
progenitor cells), nucleic acids, amino acids, peptides, polypeptides, antibodies, aptamers, 
ribozymes, guide sequences for ribozymes that inhibit translation or transcription of essential 
tumor proteins and genes, hormones, immunomodulators, antipyretics, anxiolytics, 
35 antipsychotics, analgesics, antispasmodics, anti-inflammatories, anti-histamines, anti-
infectives, and chemotherapeutics. 
8 
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In some embodiments, any of the acellular tissue scaffolds described herein can be 
administered to a subject in need thereof in the original form, as an injectable formulation, or 
as other derivatives of the acellular tissue. In some embodiments, the subject in need 
thereof has a peripheral nerve injury, spinal cord injury, spinal cord disease, amputation or 
5 otherwise suffers from degradation of a component of the spine (e.g. intervertebral disc 
degeneration). In other embodiments, the subject could have osteoarthritis of the hip or 
knee, trauma to the lungs, volumetric muscle loss, cirrhosis of the liver, or otherwise requires 
partial or total organ replacement. 
10 EXAMPLES 
Now having described the embodiments of the present disclosure, in general, the 
following Examples describe some additional embodiments of the present disclosure. While 
embodiments of the present disclosure are described in connection with the following 
examples and the corresponding text and figures, there is no intent to limit embodiments of 
15 the present disclosure to this description. On the contrary, the intent is to cover all 
alternatives, modifications, and equivalents included within the spirit and scope of 
embodiments of the present disclosure. 
Example 1: 
Peripheral nerves were harvested from Sprague Dawley rats and decellularized 
20 according to an apoptosis-assisted protocol using 5 IJM camptothecin in non-supplemented 
media at 3rC for 1 day. Tissue in media without camptothecin, an apoptotic agent, was 
used as a control. Apoptotic agent treatment was succeeded by washes in saline buffered 
solutions to optimize cell removal. Furthermore, the tissue was treated with 75 u/mL DNAse 
for 24 hours to ensure DNA removal. The degree of apoptosis, cellular removal, and matrix 
25 preservation was assessed using immunochemistry on nerve tissue sections and 
fluorescence imaging (Fig 2). Antibodies used to identify apoptosis, cell removal, and tissue 
preservation include those against active caspase 3 (Abcam); neurofilament (RT-97, DSHB) 
and S100 (Dako); and laminin (Sigma), respectively. Fig. 2A shows immunochemical 
staining of a fresh peripheral nerve used as a no treatment control. Figs. 2B and 2C show 
30 nerves treated with 5 IJM for 1 day, washed with a hypertonic, and either washed with a 
hypertonic solution or treated for 24 hours with DNAse, respectively. Fig. 20 shows staining 
of a fresh nerve that was subjected to the same hypertonic and hypotonic washes and 
represents the results of not inducing apoptosis prior to washing the tissue. Figs. 2E and 2F 
show treatment with higher camptothecin (10 IJM), again for 1 day, and washed similarly to 
35 tissue in Figs. 2B and 2C. These images depict 1) apoptosis induction is necessary prior to 
9 
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washing to effectively remove cellular components and 2) combing apoptosis induction with 
washes in non-isotonic solutions achieves cellular removal of peripheral nerve tissue. 
Total DNA content was quantified using a Picogreen DNA assay (Life Technologies) 
according to manufacturer's instructions. DNA quantification data are shown in Figs. 3 and 4. 
5 Washing the tissue without first inducing apoptosis resulted in only a 29.8% reduction of 
DNA content compared to fresh nerve. Conversely, inducing apoptosis using 5 or 10 IJM 
camptothecin yielded a 71.9 and 57.3% reduction in DNA, respectively. Replacing the 
hypotonic wash with DNAse treatment further reduced the DNA content, with 5 and 10 IJM 
camptothecin treatment for 1 day resulting in a 95.1 and 95.8% reduction. 
10 
Example 2: 
Peripheral nerves were harvested from Sprague Dawley rats and decellularized 
according to an apoptosis-assisted protocol using 10 IJM camptothecin in non-supplemented 
media at 3rC for 2 days. Tissue in media without camptothecin was used as a control. 
15 Apoptotic agent treatment was succeeded by washes in saline buffered solutions to optimize 
cell removal. The degree of apoptosis, cellular removal, and matrix preservation was 
assessed using immunochemistry on nerve tissue sections and fluorescence imaging. 
Antibodies used to identify apoptosis, cell removal, and tissue preservation include those 
against active caspase 3 (Abcam); neurofilament (RT-97, DSH8) and S100 (Dako); and 
20 laminin (Sigma), respectively. Apoptosis-mediated DNA fragmentation was assessed using a 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Total DNA 
content was quantified using a Picogreen DNA assay (Life Technologies) according to 
manufacturer's instructions. 
Figs. 5A-5C demonstrate fluorescence micrographs of nerve tissue labeled for cell or 
25 basal lamina markers. For Figs. 5A and 58, the images are fresh nerve (top half) and 
apoptosis decellularized nerve (bottom half). Fig. 5A was labeled for neurons (neurofilament, 
green), Schwann cells (S100, red), and nuclei (DAPI, blue). Fig. 58 shows cross-sections of 
the basal lamina stained for laminin (red). Fig. 5C shows a representative basal lamina 
staining in nerve tissue decellularized according to a conventional detergent-based method. 
30 Induction of apoptosis was confirmed in treated nerve tissue by an increase in active 
caspase 3, an early mediator of apoptosis. Moreover, TUNEL staining revealed pervasive 
DNA fragmentation in treated nerves, indicating late stage apoptosis, as well. Media controls 
exhibited neither hallmark of apoptosis. Following induction of apoptosis, cellular proteins 
were easily removed using only washes in hypertonic 4X saline buffer while removal of DNA 
35 required brief washes in mildly hypotonic 0.5X saline buffer. Using this regimen, a 
substantial reduction in cellular and nuclear staining was achieved compared to fresh nerve. 
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Notably, the basal lamina microstructure was nearly identical to fresh nerve and was 
significantly improved over alternatively processed tissue. 
Treatment with camptothecin was observed to be sufficient to elicit aspects of 
apoptosis ex vivo, including caspase 3 activation and DNA fragmentation. Moreover, 
5 induction of apoptosis was observed to enable extensive removal of cellular and nuclear 
components from peripheral nerve tissue using only non-isotonic buffers. Two analogs of 
camptothecin are considered safe by the FDA, which bolsters the clinical potential of this 
apoptosis-assisted decellularization method. Ultimately, the approach demonstrated here 
and described herein can eliminate the need for harsh lysis and chemical steps in 
10 conventional protocols and pushes decellularization technology toward achieving 3D, cell-
free replicas of native tissue. 
Example 3: 
Cervical and lumbar segments were removed Yorkshire-Landrace porcine. Each 
15 motion segment was carefully dissected to extract the nucleus pulposus as shown in Figure 
7. Nucleus pulposi were decellularized according to an apoptosis-assisted protocol using 10 
IJm camptothecin in standard non-supplemented culture media for 24 hours. Control 
samples were also processed in parallel without camptothecin. After induction of apoptosis, 
samples were washed in a series of hypertonic and hypotonic buffers to remove apoptotic 
20 cell bodies (Table 1). 
Table 1 
Wash Type Method 
Hypertonic 2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min 
Hypotonic 0.5X PBS 1Shrs, 1X PBS 30min 
Hyper-Hypo 2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min, 0.5X PBS 6hr, 
1X PBS 30min 
Hypo-Hyper 0.5X PBS 1Shrs, 1X PBS 30min, 2X PBS 30min, 4X PBS 6hrs, 2X PBS 30min, 
1X PBS 30min 
Hyper-DNase 2X PBS 30min, 4X PBS 1Shrs, 2X PBS 30min, 1X PBS 30min, 24hrs DNase, 
1X PBS 45 mins 
No Wash Fix Immediately after 24hrs in media. 
After washes, samples were processed for fixed and stained using DAPI (Thermo Fisher, 
01306) to detect removal of cell nuclei, and a chondroitin sulfate proteoglycan (CSPG) 
antibody (Sigma, CS035) to examine maintenance of key proteins. Confocal imaging was 
11 
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used to assess removal of cell nuclei and maintenance of CSPGs. Results demonstrated in 
Figs. 6A-6D suggest the hypertonic wash and the hypertonic-hypotonic wash substantially 
remove cell nuclei while maintaining desired CSPGs. 
Example 4: 
Rat sciatic nerve was isolated from Sprague Dawley rats and decellularized using 
either standard detergent-based methods or apoptosis induction and tonic wash methods as 
detailed in Example 1 above. A rat transection model of nerve injury was performed in Lewis 
rats to determine efficacy of apoptosis decellularized samples compared to detergent 
decellularized samples, fresh harvested Lewis isograft sciatic nerves, and a sham control 
10 group. Briefly, sciatic nerve was transected and 8 mm of sciatic nerve was then removed to 
create a 10 mm nerve gap. After transection, one of three samples was implanted via direct 
suture to the nerve stumps (detergent, apoptosis, or isograft). Implants and sham controls 
were harvested at 4 weeks (n=3) and 8 weeks (n=6) for histological analysis. Tibialis anterior 
muscles were also harvested and weighed at 4 and 8 weeks to determine degree or re-
15 innervation of a distal target, an indirect assessment of regeneration. 
Results are shown in Fig. 8 and indicate that apoptosis decellularized samples 
enhance muscle recovery compared to detergent decellularized samples at both weeks 4 
and 8, and are approaching levels of the isograft gold standard treatment.. Throughout the 
time course of the study (2,4,6, and 8 weeks), animals were also recorded while walking on 
20 a track to analyze alterations in gait (data not shown). Histology was used to assess the 
degree of regeneration between groups at both 4 weeks and 8 weeks. (data not shown). 
12 
WO 2017/011653 PCT/US2016/042273 
We claim: 
1. A tissue deceliularization method comprising: 
obtaining a tissue sample from a subject to generate an ex vivo tissue 
sample; 
exposing the ex vivo tissue sample to an apoptotic agent or apoptotic 
process; and 
solution, 
washing the ex vivo tissue sample in a hypertonic solution, a hypotonic 
or a hypertonic solution and a hypotonic solution. 
2. The method of claim 1, wherein the tissue sample is a peripheral nerve, a 
nucleus pulposus, or a combination thereof. 
3. The method of claim 1, wherein the tissue sample is lung tissue. 
4. The method of claim 1, wherein the apoptotic agent is camptothecin, 
staurosporine, doxorubicin, or an analog thereof. 
5. The method of claim 1, wherein the apoptotic process comprises one or more 
freeze-thaw cycles. 
6. The method of claim 1, wherein the concentration of the apoptotic agent 
ranges from about 5IJM to about 10 IJM. 
7. The method of claim 1, wherein the concentration of the apoptotic agent is 
about 10 IJM. 
8. The method of claim 1, wherein the concentration of the apoptotic agent is 
about 5 IJM. 
9. The method of claim 1, wherein the ex vivo tissue sample is exposed to the 
apoptotic agent for about 2 days. 
10. The method of claim 1, wherein the tissue is washed with a hypertonic 
solution. 
11. The method of claim 10, wherein the hypertonic solution is greater than 1X 
buffered solution. 
13 
WO 2017/011653 PCT/US2016/042273 
12. The method of claim 10, wherein the hypertonic solution is 4X saline. 
13. The method of claim 1, wherein the tissue is washed with a hypotonic 
solution. 
14. The method of claim 13, wherein the hypotonic solution is less than 1X 
buffered solution. 
15. The method of claim 13, wherein the hypotonic solution is a 0.5X saline 
solution. 
16. The method of claim 13, wherein the concentration the concentration of the 
apoptotic agent is about 5 IJM. 
17. The method of claim 16, wherein the apoptotic agent is camptothecin, 
staurosporine, doxorubicin, an analog thereof. 
18. The method of anyone of claims 1, 8, or 13-17, further comprising the step of 
treating the tissue with DNAse for a period of time ranging from 30 minutes to 24 hours. 
19. The method of claim 1, wherein the step of washing produces an acellular 
tissue product. 
20. The method of claim 19, further comprising the step of adding an active agent 
to the acellular tissue product. 
21. The method of claim 20, wherein the active agent is selected from the group 
consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide, antibody, aptamer, 
ribozyme, guide sequence for a ribozyme that inhibit translation or transcription of essential 
tumor proteins and genes, hormone, immunomodulator, antipyretic, anxiolytic, antipsychotic, 
analgesic, antispasmodic, anti-inflammatory, anti-histamine, anti-infective, a 
chemotherapeutic, or combinations thereof. 
22. An acellular tissue product, where the acellular tissue product is formed by a 
method according to anyone of claims 1-17. 
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23. The acellular tissue product of claim 22, wherein the method further includes 
the step of treating the tissue with DNAse for a period of time ranging from 30 minutes to 24 
hours. 
24. The acellular tissue product of claim 22, further comprising an active agent. 
25. The acellular tissue product of claim 23, wherein the active agent is selected 
from the group consisting of: a stem cell, nucleic acid, amino acid, peptide, polypeptide, 
antibody, aptamer, ribozyme, guide sequence for a ribozyme that inhibit translation or 
transcription of essential tumor proteins and genes, hormone, immunomodulator, antipyretic, 
anxiolytic, antipsychotic, analgesic, antispasmodic, anti-inflammatory, anti-histamine, anti-
infective, a chemotherapeutic, or a combinations thereof. 
26. The acellular tissue product of anyone of claims 22-25, wherein the acellular 
tissue product is formulated for injection. 
27. A method comprising: 
administering an acellular tissue product as in anyone of claims 19-21 or 22-26 to a 
subject in need thereof. 
28. The method of claim 27, where the subject in need thereof has a spinal injury 
or disease, intervertebral disc degeneration, disease or trauma of the lungs or liver, or 
volumetric muscle loss, peripheral nerve injury, amputation or spinal degradation, 
osteoarthritis of the hip or knee, volumetric muscle loss, cirrhosis of the liver, or otherwise 
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